Article
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
British journal of cancer - 1 Feb 2022
Quintanilha Julia C F, Wang Jin, Sibley Alexander B, Jiang Chen, Etheridge Amy S, Shen Fei, Jiang Guanglong, Mulkey Flora, Patel Jai N, Hertz Daniel L, Dees Elizabeth Claire, McLeod Howard L, Bertagnolli Monica, Rugo Hope, Kindler Hedy L, Kelly William Kevin, Ratain Mark J, Kroetz Deanna L, Owzar Kouros, Schneider Bryan P, Lin Danyu, Innocenti Federico
Abstract excerpt
BACKGROUND: Hypertension and proteinuria are common bevacizumab-induced toxicities. No validated biomarkers are available for identifying patients at risk of these toxicities. METHODS: A genome-wide association study (GWAS) meta-analysis was performed in 1039 bevacizumab-treated patients of European ancestry in four clinical trials (CALGB 40502, 40503, 80303, 90401). Grade ≥2 hypertension and proteinuria were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.